114 results about "Galactosamine" patented technology

The invention relates to the technical field of pharmaceutical preparations, and discloses a composition with liver protection and antioxidation effects and a preparation method thereof.The composition is prepared from galactosamine modified astragalus membranaceus exosome, schisandra chinensis nanocrystals, liquorice-chitosan nanoparticles, lactobacillus acidophilus freeze-dried powder, beta-(1, 3) / (1, 3, 4-tetramethyl-1, 3-pentanediol monoisobutyrate) sourced from saccharomyces cerevisiae, and beta-(1, 3, 4-tetramethyl-1, 3-pentanediol monoisobutyrate). And (6) a dextran, grape exosome-curcumin hybrid vesicle freeze-dried powder, a curcumin-mitochondrial targeting peptide compound, a resveratrol-hydroxypropyl-beta-cyclodextrin inclusion compound and reduced panthenol. According to the liver-protecting and anti-oxidation composition disclosed by the invention, multi-dimensional intervention on liver protection is realized through an elaborately designed ternary system. The system is composed of a traditional Chinese medicine extract, a microorganism-plant exosome combination and a high-bioavailability antioxidant, all the parts have a synergistic effect, and the liver protection effect is remarkably improved.

The invention discloses a composition for resisting porcine viral diarrhea and application of the composition. The composition for resisting porcine viral diarrhea is prepared from the following components in parts by mass: 2 parts of phloretin, 1 part of N-acetyl-D-galactosamine and 100 parts of proline. The composition can further comprise one or more auxiliary materials of absolute ethyl alcohol, propylene glycol, dimethyl sulfoxide, edible oil, water, tween-80, lactose, defatted rice bran, corncob powder, soluble starch, bran, silicon dioxide, montmorillonite, vermiculite, medical stone, zeolite powder, white carbon black and the like. The composition can significantly inhibit the proliferation of PEDV, TGEV and PoRV, and inhibit the infection of PEDV, TGEV and PoRV on cells, and further, the composition can be used for preparing drugs or feed additives for resisting porcine diarrhea diseases caused by viruses such as PEDV, TGEV and PoRV.

The invention relates to the technical field of aquaculture, in particular to a leiocassis longirostris intestinal health functional additive based on spermaceti soxhlet metabolite. The Leiocassis longirostris intestinal health functional additive comprises the following functional components: chondroitin sulfate, N-acetyl-D-galactosamine, 4 ', 4', 4 ', 4', 4 ', 4', 4 ', 4', 4 ', 4', 4 ', 4'- The composition is prepared from the following raw materials: 4, 6-dihydroxyflavone, polydatin, ascorbic acid, glucoside, arabinogalactan, 3-O-beta-D-galactopyranosyl-L-arabinose, tyramine, 4A-hydroxytetrahydrobiopterin, hyaluronic acid and 3-mercapto-2-butanol. According to the technical scheme, the technical problem that an existing probiotic viable bacterium preparation is difficult to meet the intestinal health management requirement in intensive culture of the leiocassis longirostris can be solved. Compared with the prior art, the scheme is more efficient, stable and safe, healthy development of the Leiocassis longirostris breeding industry can be effectively promoted, and the method has ideal application and popularization prospects.

The invention discloses a gymnadenia conopsea octasaccharide-decaose mixture as well as a preparation method and application thereof, and belongs to the technical field of medicines. The monosaccharide of the octasaccharide-decataccharide mixture of the gymnadenia conopsea comprises N-acetamino galactose, fucose, glucuronic acid or sugar alcohol thereof, galactose, N-acetylglucosamine, dehydrated talose and a sulfate group. The octasaccharide to decataccharide mixture of the gymnadenia conopsea disclosed by the invention can be used for remarkably prolonging the time of activating partial thromboplastin and prothrombin and effectively inhibiting endogenous and common coagulation pathways. The octasaccharide-decaose mixture of the gymnadenia conopsea can be used as a potential endogenous factor X enzyme inhibitor for preparing medicines for treating thrombotic cardiovascular diseases.

The present disclosure provides, in part, conjugates of N-actylgalactosamine (GalNAc) and oligonucleotides are their methods of use in inhibiting gene expression and the treatment of various disorders.

The invention relates to the field of enzyme and protein structures, in particular to fusion protease as well as a construction method and application thereof. The construction method comprises the following steps: carrying out gene recombination on the FpGalNAcDeAc and the FpGalNase, and carrying out prokaryotic expression and purification, so as to obtain the FpGalNAcDeAc-FpGalNase or the FpGalNase-FpGalNAcDeAc. The construction method comprises the following steps: carrying out gene recombination on the FpGalNAcDeAc and the FpGalNase; the invention describes that under the conditions of specific buffer solution, incubation time and enzyme concentration, A type red blood cells can be converted into universal O type red blood cells with maximum efficiency. The structure of galactosaminase is analyzed by using a cryoelectron microscope, and acetylgalactosamine deacetylase and galactosaminase are subjected to fusion expression, so that more efficient erythrocyte type conversion is carried out. The method can be used for rapidly, efficiently and safely carrying out type-A erythrocyte type conversion, and has the advantages of high protease yield, low working concentration, simple and convenient conversion operation, universal conditions, low cost and the like.

The disclosure provides methods for synthesis of peracetylgalactosamine-1-pentanoic acid, also called peracetylated D-galactosamine C5 linker or GalNAc C5 linker, using a vegetal source as a starting material, such as vegetal-sourced D-glucosamine or D-glucosamine hydrochloride. Also provided are methods for purifying the peracetylgalactosamine-1-pentanoic acid, or GalNAc C5 linker, thus produced so that the end product comprises fewer impurities.

The invention discloses an analysis method for determining the content of galactosamine in sulfated polysaccharide based on high-temperature hydrochloric acid hydrolysis and an ion chromatograph method, which comprises the following steps: hydrolyzing a test sample with hydrochloric acid at high temperature to release galactosamine, separating with an ion chromatograph and a sugar analysis column, detecting with a pulsed ampere detector, and determining the content of galactosamine in sulfated polysaccharide according to a galactosamine reference substance. And quantitatively analyzing the content of galactosamine in the test sample. The method disclosed by the invention has the advantages of simplicity, rapidness, accuracy, high efficiency, no need of derivation treatment and the like.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as small interfering RNA (siRNA) molecules, able to inhibit proprotein convertase subtilisin kexin 9 (PCSK9) gene expression. Also disclosed are pharmaceutical compositions that include PCSK9 RNAi agents and methods of use thereof. The PCSK9 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the PCSK9 RNAi agents in vivo provides for in vivo provides for inhibition of PCSK9 gene expression and thereby reduction of PCSK9 protein. The RNAi agents can be used in methods of treatment of diseases or disorders mediated at least in part by PCSK9 gene expression, including among others hypercholesterolemia, familial hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), familial hypobetalipoproteinemia, hyperlipidemia, coronary artery disease, polygenic dyslipidemia, heart disease, cardiovascular disease (CVD) including clinical atherosclerotic cardiovascular disease (ASCVD).

The invention belongs to the technical field of ocean, and particularly relates to sea cucumber polysaccharide with an anti-colitis effect and application of the sea cucumber polysaccharide. According to the invention, the holothuria leucospilota polysaccharide H.leucospilota PS with a brand new structure is separated and purified from holothuria leucospilota, and the holothuria leucospilota polysaccharide H.leucospilota PS is composed of five monosaccharides, namely glucosamine, glucuronic acid, galactosamine, galactose and fucose. According to the present invention, by changing the intestinal microflora structure, the polysaccharide further regulates the generation of 3-Hydroxybutyrate, L-Meliic acid and Succinic semialdehydes, such that the intestinal energy metabolism is regulated, the intestinal microflora disorder and the energy metabolism disorder caused by the colitis are improved, and the drug resistance and the side effect caused by the long-term taking of the colitis treatment agent can be avoided;

The invention discloses raspberry leaf polysaccharide as well as a preparation method and application thereof. The average relative molecular weight of the raspberry leaf polysaccharide is 44755 Da, and the raspberry leaf polysaccharide is mainly prepared from mannose, glucose, rhamnose, glucosamine, galactosamine, glucuronic acid, galactose, xylose and arabinose according to the molar ratio of (3.138): (0.894): (12.349): (4.590): (26.498): (18.681): (22.842): (2.690): (8.317). Besides, methylation and nuclear magnetic resonance analysis show that the raspberry leaf polysaccharide is complex polysaccharide, and it can be reasonably deduced that the raspberry leaf polysaccharide is mainly composed of a large number of HG structural domain-like structures and a part of RG-I structures with side chains. Meanwhile, the raspberry leaf polysaccharide disclosed by the invention can be used for inhibiting the injury of kidney tissues and reducing the generation of kidney inflammatory factors.

The invention discloses a synthesis method of a trivalent GalNAc compound, which comprises the following steps: under the action of a condensing agent and organic alkali, reacting carboxyl-containing D-galactosamine pentaacetate as shown in a formula I with carbobenzoxy-protected diamine as shown in a formula II to obtain an intermediate III; under the hydrogen atmosphere, the intermediate III reacts under the catalysis of palladium carbon to remove a carbobenzoxy protecting group, and an intermediate IV is obtained; under the action of a condensing agent and organic alkali, the intermediate IV reacts with tri [(2-carboxyl ethyoxyl) methyl] methyl benzyl carbamate, and the trivalent GalNAc compound shown in the formula V is obtained. The method is simple and rapid in reaction process, mild in condition, simple and convenient in post-treatment, and high in target product yield which at least reaches about 55% and is obviously higher than that in the prior art.

The invention relates to the technical field of culture media, and particularly discloses a candida chromogenic culture medium as well as a preparation method and application thereof. The candida chromogenic culture medium disclosed by the invention is prepared from the following components in concentration: 10 to 11 g / L of peptone, 12 to 17 g / L of agar, 7 to 9 g / L of glucose, 1 to 2 g / L of chromogenic substrate and 0.4 to 0.6 g / L of bacteriostatic agent, the chromogenic substrate is formed by mixing heavy 4-nitrophenyl-N-acetyl-beta-D-galactosamine and 4-methylumbelliferone-beta-D-N-acetyl galactosamine, and the chromogenic substrate is formed by mixing heavy 4-nitrophenyl-N-acetyl-beta-D- The bacteriostatic agent is prepared by mixing chloramphenicol, taurocholic acid and nalidixic acid. When being used for detecting and identifying candida albicans, candida tropicalis, candida krusei and candida glabrata, the chromogenic culture medium provided by the invention has strong specificity, short identification time and wide practical application value.

The invention discloses a fluorescent probe for identifying D-galactosamine as well as a preparation method and an identification method thereof, and belongs to the technical field of chemical analysis and detection. The fluorescent probe takes BINOL as a skeleton, and the preparation method of the fluorescent probe comprises the following steps: sequentially synthesizing intermediates (R)-2, (R)-3 and (R)-4, dissolving (R)-4 in a mixed solution of absolute ethyl alcohol and dichloromethane, adding hydrochloric acid, reacting overnight, quenching, separating a water phase and an organic phase, removing a solvent under reduced pressure, and purifying by a silica gel column to obtain a yellow solid product (R)-5, namely the fluorescent probe. The fluorescent probe disclosed by the invention is simple to prepare and low in cost, the D-galactosamine (D-GalN) can be identified from various amino sugars and amino acids in acetonitrile, and the detection method is simple to operate, high in sensitivity and convenient in post-treatment.

The current invention concerns methods for the synthesis of 6-azido-6-deoxy-2-N-acetyl-monosaccharide-nucleoside diphosphate, in particular 6-azido-6-deoxy-2-N-acetyl-D-galactosamine-nucleoside diphosphate or 6-azido-6-deoxy-2-N-acetyl-D-glucosamine-nucleoside diphosphate. The synthesis method according to the invention is characterized by being highly efficient and high yielding. Also part of the present invention are key intermediates of this process.

The application discloses a preparation method of a liver-targeting drug delivery carrier, and comprises the following steps: synthesizing bromic acid N-acetylgalactosamine ester; and synthesizing the liver-targeting drug delivery carrier. x The liver-targeting drug delivery carrier GalNAc-C x CD is designed based on bromic acid N-acetylgalactosamine ester Br-C GalNAc and beta-cyclodextrin, which can include poorly soluble drugs to be delivered to the liver and released in a targeted manner, greatly improves the targeting efficiency on the liver, and the targeting delivery rate can reach more than 70%, while effectively improving the solubility and bioavailability of the poorly soluble drugs, improving the drug treatment effect, providing a new strategy for the delivery of other poorly soluble drugs for treating liver diseases, and laying a foundation for the development of drugs and functional foods for intervening NASH.

The present disclosure provides a combination comprising an antibody that specifically binds to C5 and a C5 iRNA, which is a glycoconjugate containing a ligand with a terminal N-acetylgalactosamine (GalNAc) residue and / or N-acetylglucosamine (GlcNAc) residue. A method for reducing degradation of glycoconjugate RNA by the beta-hexosaminidase enzyme is also provided. The present disclosure also includes a method for treating or preventing a C5-related disease or disorder by administering one or more doses of an anti-C5 antibody or antigen-binding fragment thereof in combination with one or more doses of a C5 iRNA; preferably, the anti-C5 antibody or fragment and the C5 iRNA are in a combination. The present disclosure also includes a dosing regimen for treating a C5-related disease or disorder with a combination of an anti-C5 antibody and a C5 iRNA in either a treatment-naive subject or a subject switching from a previous C5 inhibitor therapy.

The present invention discloses a Sepia esculenta ink polysaccharide for improving high-glucose damage of endothelial cells, and a preparation method and application thereof. The Sepia esculenta ink polysaccharide has a polysaccharide backbone composed of fucose, galactosamine, mannose, and N-acetylglucosamine, and has a glucuronic acid branch chain at the C-3 position of mannose. It is an aminopolysaccharide with a weight-average molecular weight of 10-16 kDa and a sulfation degree of 8%-15%. Through experimental verification, compared with similar compounds, the Sepia esculenta ink polysaccharide can effectively improve the state of endothelial cells and maintain the normal filtration function of vascular endothelium. At the same time, the risk of bleeding side effects of the Sepia esculenta ink polysaccharide is significantly lower than that of similar polysaccharides, and it has higher safety in use. Furthermore, the Sepia esculenta ink polysaccharide can be used to develop adjuvant therapeutic drugs for late-stage diabetic lesions, filling the gap in such products on the current market.

The current invention concerns methods for the synthesis of 6-azido-6-deoxy-2-N-acetyl-monosaccharide-nucleoside diphosphate, in particular 6-azido-6-deoxy-2-N-acetyl-D-galactosamine-nucleoside diphosphate or 6-azido-6-deoxy-2-N-acetyl-D-glucosamine-nucleoside diphosphate. The synthesis method according to the invention is characterized by being highly efficient and high yielding. Also part of the present invention are key intermediates of this process.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

The present disclosure relates to RNAi agents, e.g., double-stranded RNAi agents, capable of inhibiting the expression of a mitochondrial amidoxime reducing component 1 (MARC1) gene. Also disclosed are pharmaceutical compositions comprising the MARC1 RNAi agent and methods of using the same. In some embodiments, the MARC1 RNAi agents disclosed herein can be conjugated to targeting ligands, including ligands comprising N-acetyl-galactosamine, to facilitate delivery to hepatocytes. Delivery of the MARC1 RNAi agent in vivo provides inhibition of MARC1 gene expression. RNAi agents may be used in methods of treating diseases, disorders or conditions mediated in part by MARC1 gene expression, including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease, autoimmune hepatitis, hepatic fibrosis, cirrhosis, elevated blood cholesterol levels, hypertriglyceridemia, liver disease, and / or other MARC1 related diseases.

The application belongs to the technical field of biological medicine, and particularly relates to a galactosamine-doxetaxel conjugate as well as a preparation method and application thereof. First, doxetaxel and 3,3'-diseleno-dipropionic acid are used as raw materials, and after heating reaction, 3,3'-diseleno-dipropionic acid doxetaxel is obtained. Then, the obtained 3,3'-diseleno-dipropionic acid doxetaxel and galactosamine are used as raw materials, and after heating reaction, galactosamine-3,3'-diseleno-dipropionic acid doxetaxel conjugate is obtained through column chromatography separation and purification. The obtained conjugate can be specifically recognized by endogenous lectin receptors (such as asialoglycoprotein receptor ASGPR) which are highly expressed on the surface of hepatoma cells, so as to be taken up by hepatoma cells through a receptor-mediated pathway, and has application prospect in the direction of hepatoma targeted treatment.

The invention discloses lake sphingosine bacteria AT4-200, exopolysaccharides thereof and application of the lake sphingosine bacteria AT4-200 in promoting plant growth and improving plant stress resistance, relates to the technical field of microbial technology and biostimulant application, and discloses the lake sphingosine bacteria AT4-200 separated and purified from tobacco rhizosphere and the exopolysaccharides generated by the lake sphingosine bacteria AT4-200, the molecular weight of the exopolysaccharides is about 1340Da, and the exopolysaccharides can be applied to plant growth promotion and plant stress resistance improvement. The polysaccharide mainly comprises five monosaccharides, namely mannose, glucose, glucosamine, galactosamine and rhamnose. Application verifies that the strain and / or exopolysaccharide thereof can significantly increase agronomic characters such as leaf area and dry weight of tobacco, can effectively improve salt tolerance of soybean under salt stress, and can be used as a novel, low-cost and efficient plant biostimulant or stress-resistant preparation.

The problem addressed by the present invention is to provide: a novel method for preparing an N-acetyl-D-galactosamine ligand oligonucleotide conjugate, in particular, a novel method for preparing an N-acetyl-D-galactosamine unit; and a novel intermediate. In a novel process for the preparation of N-acetyl-D-galactosamine units, studies have been made regarding the selective deprotection of benzyl groups using a palladium catalyst. As a result, a novel preparation method and a novel intermediate which can achieve high quality and high yield and are industrially advantageous are found, which results in the completion of the invention.

The present invention discloses a double-stranded nucleic acid-galactosamine-cholesterol compound and its application, and belongs to the technical field of nucleic acid drugs. The double-stranded nucleic acid-galactosamine-cholesterol compound is composed of a double-stranded nucleic acid, galactosamine and cholesterol connected in sequence; wherein, the double-stranded nucleic acid is a double-stranded nucleic acid with the function of inhibiting the transcription level and / or expression level of the target gene, and is composed of an antisense nucleic acid chain and a complementary chain; the galactosamine is connected to the 5' end of the complementary chain of the double-stranded nucleic acid. The double-stranded nucleic acid-galactosamine-cholesterol compound is used in the preparation of a drug that has the effect of inhibiting the transcription level and / or expression level of the target gene and has a protective effect on the kidney. The double-stranded nucleic acid-galactosamine-cholesterol compound of the present invention can penetrate the blood-brain barrier and can significantly reduce the burden on the kidney, providing a technical platform for the treatment of refractory diseases of the nervous system such as Alzheimer's disease and Parkinson's disease.

The present disclosure relates to RNAi agents able to inhibit Complement Factor B (CFB) gene expression. Also disclosed are pharmaceutical compositions that include CFB RNAi agents and methods of use thereof. The CFB RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the in vivo delivery to hepatocyte cells. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), Anti-Glomerular Basement Membrane disease (anti-GBM), ischemia reperfusion injury and T-cell mediated rejection (TCMR) in kidney transplantation, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD), including early and / or intermediate AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated diseases.

The invention relates to the fields of biotechnology and molecular biology; specifically, to nucleic acid-based technologies. therapeutic agents, RNA interference (RNAi) technologies, oligonucleotides for gene silencing This relates to the design and targeted ligand conjugation of these ligands. More specifically... The invention, as described, provides hepatocyte-targeted gene silencing with N-acetylgalactosamine (GalNAc). conjugated, Seipin gene-specific oligonucleotide sequence (siSeipin) and abnormalities of this sequence It relates to its application in liver diseases associated with lipid accumulation.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit Yellow Fever Virus (YFV) viral genome expression. Also disclosed are pharmaceutical compositions that include YFV RNAi agents and methods of use thereof. The YFV RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the YFV RNAi agents in vivo provides for inhibition of YFV viral genome expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms caused by YFV infection, such as liver failure.

The invention relates to the technical field of anti-oxidation free radical eliminating drugs and anti-inflammatory activity, in particular to a preparation method of N-acetyl-D-galactosaminated astaxanthin / chitosan microspheres, a product and application of the N-acetyl-D-galactosaminated astaxanthin / chitosan microspheres. According to the preparation method, N-acetyl-D-galactosamine is taken as a ligand molecule, chitosan is taken as a microsphere carrier, chitosan coats astaxanthin to form chitosan microspheres, N-acetyl-D-galactosamine is used for modifying the chitosan microspheres on the outer layer, and finally the N-acetyl-D-galactosamine aminated astaxanthin / chitosan microspheres are formed. According to the invention, the biological limitation of the astaxanthin is improved, the water solubility of the astaxanthin is improved, and the bioavailability of the astaxanthin is improved. And the N-acetyl-D-galactosamine and the chitosan are natural materials which are non-toxic, degradable and easy to absorb by a human body, so that the safety is high.

We provide a technology that can activate NRF2. [Solution] An NRF2 activator comprising one or more chondroitin sulfate oligosaccharides selected from (a) to (c) below as an active ingredient: (a) a disaccharide having a chondroitin sulfate structure (a disaccharide of CS), (b) a trisaccharide having two N-acetyl-D-galactosamine residues and a chondroitin sulfate structure (a trisaccharide of CS having two GalNac residues), (c) a tetrasaccharide having a chondroitin sulfate structure (a tetrasaccharide of CS). According to the present invention, NRF2 can be activated. This is expected to promote homeostatic reactions in the body, such as antioxidant reactions, anti-inflammatory reactions, and detoxification reactions, and contribute to maintaining and improving health. It is also expected to contribute to the prevention and improvement of various unhealthy conditions and diseases caused by oxidative stress, inflammation, and toxic chemicals.